Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
B. Singh, G. Mal, L. Bissi, F. Marotta
Alteration in gut microbiome is a major underlying causative factor of diverse inflammatory and metabolic diseases. Role of probiotics to promote perinatal health, prevention of obesity, irritable bowel syndrome are the current hot topics of research. The bioengineered probiotics with multiple immunogenic and antagonistic properties can deliver drugs, therapeutic proteins into host cells. Already the probiotics have been engineered for their stress tolerance profile, overcoming the physiochemical stresses of the host, and their applications in human nutrition and health. The aim of this article is to provide interest on mining the host microbiota for novel therapeutics and using designer probiotics as therapeutics and nutraceuticals in clinical practice. At the same time, novel high-throughput technologies such as NGS (New Generation Sequencing) allow a much more detailed and stable analysis of the microbiota than the one done by PCR so to direct industries in designing more selected mixtures and physicians to tentatively apply a more tailor-made gut eco-system interventions and rely on a reliable follow up tool.